Moomoo 24/7 ·  08/31/2023 03:56
FibroGen Shares Are Trading Lower After the Company's Phase 3 Trial of Pamrevlumab Did Not Meet Its Primary Endpoint.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment